Cargando…
Participant outcomes and preferences in Alzheimer's disease clinical trials: The electronic Person-Specific Outcome Measure (ePSOM) development program
INTRODUCTION: Current pharmacological interventions for Alzheimer's dementia delay symptom progression for about a year. Although the outcomes in earlier disease states may include changes in biomarkers, the clinical effectiveness of any intervention can ultimately only be assessed by a patient...
Autores principales: | Saunders, Stina, Muniz-Terrera, Graciela, Watson, Julie, Clarke, Charlotte L., Luz, Saturnino, Evans, Alison R., Ritchie, Craig W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296160/ https://www.ncbi.nlm.nih.gov/pubmed/30581975 http://dx.doi.org/10.1016/j.trci.2018.10.013 |
Ejemplares similares
-
Impact of clinical symptoms and diagnosis: the electronic Person-Specific Outcome Measure (ePSOM) development programme
por: Saunders, S., et al.
Publicado: (2022) -
What matters to people with memory problems, healthy volunteers and health and social care professionals in the context of developing treatment to prevent Alzheimer's dementia? A qualitative study
por: Watson, Julie, et al.
Publicado: (2019) -
Application of Big Data and Artificial Intelligence technologies to dementia prevention research: an opportunity for low-and-middle-income countries
por: Danso, Samuel O, et al.
Publicado: (2019) -
Correction to: Assessing and disclosing test results for ‘mild cognitive impairment’: the perspective of old age psychiatrists in Scotland
por: Saunders, Stina, et al.
Publicado: (2022) -
Assessing and disclosing test results for ‘mild cognitive impairment’: the perspective of old age psychiatrists in Scotland
por: Saunders, Stina, et al.
Publicado: (2022)